If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Francesco Fabbri is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
docetaxel Medicine & Life Sciences
Cell Line Medicine & Life Sciences
Cells Chemical Compounds
zoledronic acid Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Apoptosis Medicine & Life Sciences
Circulating Neoplastic Cells Medicine & Life Sciences
Tumors Chemical Compounds

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2004 2019

  • 978 Citations
  • 19 h-Index
  • 44 Article
  • 1 Review article

Genomic stability, anti-inflammatory phenotype, and up-regulation of the RNAseH2 in cells from centenarians

Storci, G., De Carolis, S., Papi, A., Bacalini, M. G., Gensous, N., Marasco, E., Tesei, A., Fabbri, F., Arienti, C., Zanoni, M., Sarnelli, A., Santi, S., Olivieri, F., Mensà, E., Latini, S., Ferracin, M., Salvioli, S., Garagnani, P., Franceschi, C. & Bonafè, M., Sep 2019, In : Cell Death and Differentiation. 26, 9, p. 1845-1858 14 p.

Research output: Contribution to journalArticle

Genomic Instability
Interferon Type I
Anti-Inflammatory Agents
DNA Damage

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer

Pietri, E., Massa, I., Bravaccini, S., Ravaioli, S., Tumedei, M. M., Petracci, E., Donati, C., Schirone, A., Piacentini, F., Gianni, L., Nicolini, M., Campadelli, E., Gennari, A., Saba, A., Campi, B., Valmorri, L., Andreis, D., Fabbri, F., Amadori, D. & Rocca, A., Jan 1 2018, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Androgen Receptors
Breast Neoplasms
Estrogen Receptors
Aromatase Inhibitors
1 Citation (Scopus)
Circulating Neoplastic Cells
Fluorescence In Situ Hybridization
Fluorescent Antibody Technique
1 Citation (Scopus)
S Phase
Ovarian Neoplasms
Drug Therapy
5 Citations (Scopus)

Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer

Rocca, A., Cecconetto, L., Passardi, A., Melegari, E., Andreis, D., Monti, M., Maltoni, R., Sarti, S., Pietri, E., Schirone, A., Fabbri, F., Donati, C., Nanni, O., Fedeli, A., Faedi, M. & Amadori, D., May 1 2017, In : Cancer Chemotherapy and Pharmacology. 79, 5, p. 863-871 9 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Hand-Foot Syndrome